Method and compositions for inhibiting tumorigenesis

• US 20050130922A1
• Filed: 08/29/2004
• Published: 06/16/2005
• Est. Priority Date: 06/20/1997
• Status: Abandoned Application

• Current Assignee: Ariel Ruiz I Altaba, Milton Datta, Suma Datta
• Original Assignee: Ariel Ruiz I Altaba, Milton Datta, Suma Datta
• Inventors: Datta, Milton, Datta, Suma, Altaba, Ariel Ruiz i
• Application Number:
  US10/927,951
• Publication Number:
  US 20050130922A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: C12N 5/0619 Neurons
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms
• CPC Class Codes: G01N 33/5743 of skin, e.g. melanoma

Abstract

The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and Gli signaling pathway, including agents that inhibit GLI synthesis and/or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of prostate cancer. Methods of treating cancer, including prostate cancer are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH/GLI pathway.

Claims

1. A method for inhibiting the synthesis and/or expression and/or activity of a GLI protein in a cell in vitro or in vivo comprising, contacting said cell with or introducing into said cell an inhibitor or antagonist of GLI synthesis and/or expression and/or activity, said inhibitor or antagonist selected from the group consisting of a small molecule inhibitor or antagonist of GLI synthesis and/or expression and/or activity, an antisense molecule or a siRNA molecule that is complementary to at least a part of the sequence of a nucleic acid encoding the GLI protein, antibodies to GLI, and agents that exhibit mimicry to GLI or antagonism to it or control over its production, said contacting or introducing resulting in inhibition of synthesis and/or expression and/or activity of the GLI protein in said cell.

2. The method of claim 1, wherein said introducing further results in inhibition of cellular proliferation and/or inhibition of tumorigenesis.

3. The method of claim 1, wherein said cell is a tumor cell.

4. The method of claim 3, wherein said tumor cell is selected from the group consisting of gliomas, medulloblastomas, primitive neuroectodermal tumors (PNETS), basal cell carcinoma, small cell lung cancers, large cell lung cancers, tumors of the gastrointestinal tract, rhabdomyosarcomas, soft tissue sarcomas, pancreatic tumors, bladder tumors and prostate tumors.

5. The method of claim 1, wherein said GLI protein is selected from the group consisting of GLI1, GLI2 and GLI3.

6. The method of claim 1, wherein said antagonist comprises an antisense compound comprising an oligonucleotide of about 10 to 50 nucleobases in length targeted to a nucleic acid encoding a GLI protein, wherein said antisense compound inhibits the expression and/or activity of said GLI protein.

7. The method of claim 6, wherein said antisense compound has the sequence as set forth in SEQ ID NO:

33.

8. The method of claim 1, wherein said antagonist comprises a siRNA molecule, said siRNA molecule comprising a double stranded structure having a nucleotide sequence which is substantially identical to or complementary to at least a part of the gli gene in an amount sufficient to inhibit the synthesis and/or expression and/or activity of a gli gene.

9. The method of claim 8, wherein said gli gene is selected from the group consisting of gli1, gli2 and gli3.

10. The method of claim 8, wherein said siRNA hybridizes under stringent conditions to the gli gene.

11. The method of claim 8, wherein the siRNA molecule is about 20 nucleotides in length.

12. The method of claim 11, wherein the siRNA molecule is selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

13. The method of claim 1, wherein said antagonist is a small molecule inhibitor of GLI expression and/or synthesis and/or activity.

14. The method of claim 13, wherein said small molecule inhibitor is a plant alkaloid or its analogs or derivatives thereof.

15. The method of claim 14, wherein said plant alkaloid is cyclopamine or jervine or their analogs or derivatives thereof.

16. The method of claim 1, wherein said antagonist is an antibody specific for at least one of the GLI proteins.

17. The method of claim 16, wherein said antibody is a polyclonal antibody.

18. The antibody of claim 16, wherein said antibody is a monoclonal antibody.

19. An immortal cell line that produces a monoclonal antibody according to claim 18.

20. The antibody of either of claims 17 or 18, wherein said antibody is a blocking antibody and is effective as a therapeutic agent to prevent the proliferation of tumor cells in vivo.

21. The antibody of either one of claims 17 or 18, wherein said antibody is coupled to an anti-tumor drug or radioisotope for use in treating tumor cells in situ.

22. The antibody of either of claims 17 or 18, wherein said antibody is effective as a diagnostic agent to aid in identification of tumor cells in situ or in vivo.

23. The antibody of claim 22, wherein said antibody is coupled to an imaging reagent and is used for imaging of tumor cells in situ or in vivo.

24. A method of preventing and/or treating cellular debilitations, derangements and/or dysfunctions and/or hyperplastic/hyperproliferative and/or cancerous disease states in a mammal characterized by the presence and/or expression of a GLI gene or gene product, comprising administering to a mammal a therapeutically effective amount of an agent that inhibits or antagonizes the synthesis and/or expression and/or activity of a GLI molecule.

25. The method of claim 24, wherein said inhibitors/antagonists are selected from the group consisting of small molecule antagonists of GLI expression and activity, antisense compounds, siRNA nucleic acids, antibodies to GLI, and agents that exhibit mimicry to GLI or antagonism to it or control over its production.

26. The method of claim 24, wherein said GLI molecule is selected from the group consisting of GLI1, GLI2 and GLI3.

27. The method of claim 24, wherein said hyperproliferative and/or cancerous disease states are selected from the group consisting of gliomas, medulloblastomas, primitive neuroectodermal tumors (PNETS), basal cell carcinoma, small cell lung cancers, large cell lung cancers, tumors of the gastrointestinal tract, rhabdomyosarcomas, soft tissue sarcomas, pancreatic tumors, bladder tumors and prostate tumors.

28. The method of claim 25, wherein said antagonist comprises an antisense compound comprising an oligonucleotide of about 10 to 50 nucleobases in length targeted to a nucleic acid encoding a GLI protein, wherein said antisense compound inhibits the expression and/or activity of said GLI protein.

29. The method of claim 28, wherein said antisense compound has the sequence as set forth in SEQ ID NO:

33.

30. The method of either one of claims 28 or 29, wherein said antisense compound, upon administering to said mammal, results in the inhibition of expression and/or activity of said GLI protein in the cells of said mammal.

31. The method of claim 30, wherein the delivery of said antisense compound to said mammal further results in inhibition of cellular proliferation in said mammal.

32. The method of claim 25, wherein said antagonist comprises a siRNA molecule, said siRNA molecule comprising a double stranded structure having a nucleotide sequence which is substantially identical to at least a part of the gli gene in an amount sufficient to inhibit the synthesis and/or expression and/or activity of a gli gene.

33. The method of claim 32, wherein said gli gene is selected from the group consisting of gli1, gli2 and gli3.

34. The method of claim 32, wherein said siRNA hybridizes under stringent conditions to the gli gene.

35. The method of claim 32, wherein the siRNA molecule is about 20 nucleotides in length.

36. The method of claim 35, wherein the siRNA molecule is selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

37. The method of claim 25, wherein said antagonist is a small molecule inhibitor of GLI expression and/or synthesis and/or activity.

38. The method of claim 37, wherein said small molecule inhibitor is a plant alkaloid or its analogs or derivatives thereof.

39. The method of claim 38, wherein said plant alkaloid is cyclopamine, jervine or their analogs or derivatives thereof.

40. The method of claim 25, wherein said antagonist is an antibody specific for at least one of the GLI proteins.

41. The method of claim 40, wherein said antibody is a polyclonal antibody.

42. The antibody of claim 40, wherein said antibody is a monoclonal antibody.

43. An immortal cell line that produces a monoclonal antibody according to claim 42.

44. The antibody of either of claims 41 or 42, wherein said antibody is a blocking antibody and is effective as a therapeutic agent to prevent the proliferation of tumor cells in vivo.

45. The antibody of either one of claims 41 or 42, wherein said antibody is coupled to an anti-tumor drug or radioisotope for use in treating tumor cells in situ.

46. A method of inducing a tumor cell to undergo apoptosis comprising administering an inhibitor or antagonist to the SHH/GLI signaling pathway in the cell.

47. The method of claim 46, wherein said inhibitor or antagonist is selected from the group consisting of a small molecule inhibitor or antagonist of GLI synthesis and/or expression and/or activity, an antisense molecule or a siRNA molecule that is complementary to at least a part of the sequence of a nucleic acid encoding the GLI protein, antibodies to GLI, and agents that exhibit mimicry to GLI or antagonism to it or control over its.

48. The method of claim 47, wherein said antisense molecule comprises the sequence as set forth in SEQ ID NO:

33.

49. The method of claim 47, wherein said siRNA molecule is selected from the group consisting of the nucleic acid sequences of SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

50. The method of claim 47, wherein the small molecule inhibitor of GLI synthesis and/or expression and/or activity is cyclopamine, jervine or analogs or derivatives thereof.

80. The method of either of claims 46 or 47, wherein said antagonist comprises agents that increase negative, or decrease positive acting elements affecting SHH-GLI signaling, said agents selected from the group consisting of small molecules that alter PKA kinase activity, small molecules that alter GSK3 kinase activity, small molecules that alter CK1 kinase activity, and small molecules or siRNAs/antisense RNAs that alter DYRK1 kinase activity.

51. A method of overcoming resistance to chemotherapeutic agents in tumor cells, comprising administering an antagonist or inhibitor to the SHH/GLI signaling pathway to the cell, wherein said administering results in increased sensitivity of the tumor cell to said chemotherapeutic agent and results in subsequent tumor cell death and prevention from metastasis, and wherein said antagonist or inhibitor is selected from the group consisting of a small molecule inhibitor or antagonist of GLI synthesis and/or expression and/or activity, an antisense molecule or a siRNA molecule that is complementary to at least a part of the sequence of a nucleic acid encoding the GLI protein, antibodies to GLI, and agents that exhibit mimicry to GLI or antagonism to it or control over its.

52. The method of claim 51, wherein said antisense molecule comprises a nucleic acid sequence that is complementary to the nucleic acid that encodes at least one GLI protein.

53. The method of claim 52, wherein said antisense molecule comprises the nucleic acid sequence as set forth in SEQ ID NO:

33.

55. The method of claim 51, wherein the small molecule inhibitor of GLI synthesis and/or expression and/or activity is cyclopamine, jervine or analogs or derivatives thereof.

54. The method of claim 51, wherein said siRNA molecule is selected from the group consisting of the nucleic acid sequences of SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

54-1. A method for inhibiting and/or attenuating the expression of a gli gene in a mammalian cell, said method comprising:

a) introducing into the cell an RNA having a nucleotide sequence which is substantially identical to or complementary to at least a part of the gli gene in an amount sufficient to inhibit and/or attenuate expression of a gli gene;

b) verifying inhibition and/or attenuation of expression of the gli gene; and

wherein the mammalian cell is a tumor cell or a cell obtained from tissue exhibiting hyperplasia that is characterized by the expression of at least one gli gene or gene product.

57. The method of claim 56, wherein said gli gene is selected from the group consisting of gli1, gli2 and gli3.

58. The method of claim 56, wherein said RNA is a single stranded RNA (SS-RNA) or a double stranded RNA (DS-RNA) molecule.

59. The method of claim 58, wherein said SS-RNA molecule is an antisense RNA molecule, which when administered to a mammal having a tumor cell characterized by the presence of said gli gene, results in inhibition of tumor cell proliferation.

60. The method of claim 58, wherein said DS-RNA is a siRNA molecule, which when administered to a mammal having a tumor cell characterized by the presence of said gli gene, results in inhibition of tumor cell proliferation.

61. The method of claim 60, wherein said siRNA hybridizes under stringent conditions to the gli gene.

62. The method of claim 60, wherein the siRNA molecule is about 20 nucleotides in length.

63. The method of claim 62, wherein the siRNA molecule is selected from the group consisting of the nucleic acid sequences set forth in SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

64. A double stranded siRNA for inhibiting expression of a gli gene, comprising a first nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of a gli gene and a second nucleotide sequence that is complementary to said first nucleotide sequence.

65. The siRNA of claim 64, wherein said first nucleotide sequence of said siRNA is about 20 nucleotides long.

66. The siRNA of claim 64, wherein said siRNA is selected from the group consisting of the nucleic acid sequences as set forth in SEQ ID NO:

29, SEQ ID NO;

31 and SEQ ID NO;

32.

67. The siRNA of any one of claims 64 through 66, wherein said siRNA, upon delivery to a cell containing the gli gene for which said siRNA molecules are specific, inhibits the proliferation of said cell.

68. The double stranded siRNA of claim 64, wherein the double stranded RNA is a hairpin comprising a first nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of a gli gene, and a second nucleotide sequence which is a complementary inverted repeat of said first nucleotide sequence and hybridizes to said first nucleotide sequence to form a hairpin structure.

69. A pharmaceutical composition comprising at least one inhibitor or antagonist of GLI synthesis and/or expression and/or activity and a pharmaceutically acceptable carrier.

70. The pharmaceutical composition of claim 69, wherein said inhibitor or antagonist is selected from the group consisting of a small molecule inhibitor or antagonist of GLI synthesis and/or expression and/or activity, an antisense molecule or a siRNA molecule that is complementary to at least a part of the sequence of a nucleic acid encoding the GLI protein, antibodies to GLI, and agents that exhibit mimicry to GLI or antagonism to it or control over its production, said contacting or introducing resulting in inhibition of synthesis and/or expression and/or activity of the GLI protein in said cell.

71. The pharmaceutical composition of claim 70, wherein said antisense molecule comprises the nucleic acid sequence as set forth in SEQ ID NO:

33.

72. The pharmaceutical composition of claim 70, wherein said siRNA molecule comprises the nucleic acid sequence as set forth in SEQ ID NOs:

29, 31 and 32.

73. The pharmaceutical composition of claim 70, wherein said small molecule inhibitor is cyclopamine, jervine or analogs or derivatives thereof.

74. A method of identifying a subject that is likely to be suffering from a hyperproliferative condition or a cancerous condition comprising:

determining the level of at least one GLI protein or a nucleic acid encoding at least one GLI protein in a tissue specimen or in a specimen of bodily fluid from said subject;

wherein when the level of GLI protein or a nucleic acid encoding said GLI protein determined is significantly elevated in cells obtained from said tissue or bodily fluid compared to a predetermined range of normal values established from screening individuals known to be free of a hyperproliferative or cancerous condition, the animal subject is identified as being likely to have a hyperproliferative condition or a cancerous condition.

75. The method of claim 74 wherein the determining is performed in situ or in vitro.

76. The method of claim 74, wherein the determining is performed by a method that uses a probe selected from the group consisting of an antibody specific for at least one GLI protein;

a set of primers specific for an mRNA encoding said GLI protein; and

a nucleotide probe specific for an mRNA encoding said GLI protein.

77. The method of claim 76, wherein said bodily fluid is selected from the group consisting of whole blood, serum, plasma, urine and cerebrospinal fluid.

78. A method of predicting resistance of a tumor cell to chemotherapeutic agents comprising measuring the level of expression of GLI in said tumor cell, whereby an increased level of expression of GLI in said tumor cell is predictive of resistance of said tumor cell to chemotherapeutic agents.

79. The method of claim 78, wherein said tumor cells are selected from the group consisting of gliomas, medulloblastomas, primitive neuroectodermal tumors (PNETS), basal cell carcinoma, small cell lung cancers, large cell lung cancers, tumors of the gastrointestinal tract, rhabdomyosarcomas, soft tissue sarcomas, pancreatic tumors and prostate tumors.

81. A method of screening for apoptotic resistant tumor cells, comprising measuring the level of expression of GLI in said tumor cells, wherein enhanced expression of GLI correlates with apoptosis resistance in said tumor cells.

82. The method of claim 81, wherein said tumor cells are selected from the group consisting of gliomas, medulloblastomas, primitive neuroectodermal tumors (PNETS), basal cell carcinoma, small cell lung cancers, large cell lung cancers, tumors of the gastrointestinal tract, rhabdomyosarcomas, soft tissue sarcomas, pancreatic tumors, bladder tumors and prostate tumors.